Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vitamin D receptor polymorphisms and lethal prostate cancer

A S Kibel1, S D Isaacs, W B Isaacs

  • 1James Buchanan Brady Urological Institute and Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

The Journal of Urology
|September 29, 1998
PubMed
Summary

This study found no link between vitamin D receptor (VDR) genotype and lethal prostate cancer. The vitamin D receptor genotype does not appear to be associated with aggressive prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy.

Nature communications·2020
Same author

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

TET2 binds the androgen receptor and loss is associated with prostate cancer.

Oncogene·2016
Same author

Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.

Oncogene·2016
Same author

Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2015
Same author

Association of variants in genes related to the immune response and obesity with BPH in CLUE II.

Prostate cancer and prostatic diseases·2014

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Vitamin D receptor (VDR) activity and VDR genotype have been linked to prostate cancer risk.
  • Previous studies suggest a higher risk of localized prostate cancer in individuals with less active VDR genotypes.
  • The association appears stronger in advanced prostate cancer, prompting further investigation.

Purpose of the Study:

  • To investigate the association between vitamin D receptor (VDR) genotype and lethal prostate cancer.
  • To compare the VDR genotype of patients who died from prostate cancer with that of controls without the disease.

Main Methods:

  • DNA was isolated from lethal prostate cancer patients and controls.
  • Vitamin D receptor (VDR) genotype was determined using TaqI restriction fragment length polymorphism and poly-A microsatellite repeat analysis.

Related Experiment Videos

  • Polymorphic markers identified VDR genotypes (TT, Tt, tt) and VDR alleles (L, S).

    • Main Results:

    • Strong linkage disequilibrium was observed between the TaqI and poly-A microsatellite markers.
    • No statistically significant difference was found in the distribution of VDR genotypes between prostate cancer cases and controls.
    • Both TaqI and poly-A microsatellite analyses showed similar distributions of VDR genotypes in cases and controls.

    Conclusions:

    • The study did not find an association between vitamin D receptor (VDR) genotype and lethal prostate cancer.
    • The findings do not support the hypothesis that specific VDR genotypes are linked to an aggressive prostate cancer phenotype.
    • Further research considering cofactors and refined phenotype definitions may clarify discrepancies with prior studies.